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ABSTRACT
TARGETING DESIGN TO THE LUNGAND PULMONARY INTRACELLULAR STRUCTURE
OF ENDOGENOUS GENE BY IRQ MODIFIED NANO CARRIER. Inhibition of angiogenesis is a novel
strategy for the treatment of lung cancer. For efficient therapy, vectors must firstly reach the target tissue and
subsequently demonstrate an efficient intracellular targeting. In this study, we attempted to design a vector for
in vivo pulmonary targeting which was able to deliver small interfering RibonucleicAcid (siRNA) for endogenous
gene of angiogenesis in pulmonary endothelial cells. siRNA was condensed with polycation agent and encapsulated
in lipidous nano carrier. To obtain high level of lung accumulation, we controlled the surface of nano-carrier by
changing the length of Polyethylene glycol (PEG) moiety. These nano carriers showed prominent Ribonucleic
acid interference (RNAi) effect, when luciferase gene was used as a target. In addition, an efficient transgene
knockdown of Vascular Endothelial Growth Factor Receptor 1 (VEGFR1), a responsible gene of angiogenesis,
can be obtained by the Instantaneous Respiratory Exchange Ratio (IRQ) modified nano carrier with the use of
Stearyl-R8 (STR-R8) peptide, known as an endosomal membrane inducer. In conclusion, pulmonary targeting
of nano carrier by encapsulating siRNA can be developed by controlling the PEG length and the structure of
nano carrier for efficient intracellular targeting.
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ABSTRAK
DESAIN NANO IRQ YANG DIMODIFIKASI SEBAGAI PEMBAWA AGENT ENDOGEN
DENGANTARGET KE PARU-PARU DAN INTRASELULERNYA. Penghambatan angiogenesis adalah strategi
baru dalam pengobatan kanker paru-paru. Untuk memberikan terapi yang efisien, vektor harus mencapai target
organ dan berinternalisasi secara efisien ke dalam organ tersebut. Pada penelitian ini, telah dikembangkan vektor
yang target pada paru-paru secara in vivo dan sekaligus menghantarkan small interfering Ribonucleic Acid
(siRNA) gen endogen pada sel endotel paru-paru. siRNA dikondensasi dengan senyawa polikation dan
dienkapsulasi dalam vektor lipid berukuran nano. Untuk memperoleh tingginya akumulasi di paru-paru,
permukaan dari vektor nano tersebut dikontrol dengan mengubah panjang rantai dari Polyethylene glycol (PEG).
Vektor nano yang dikembangkan menunjukkan efek Ribonucleic acid interference (RNAi) yang menonjol, saat
gen lusiferase digunakan sebagai target. Selain itu, penghambatan translasi Vascular Endothelial Growth Factor
Receptor 1 (VEGFR1), gen penentu pada angiogenesis, dapat dicapai dengan memodifikasi permukaan vektor
Instantaneous Respiratory Exchange Ratio (IRQ) dengan peptide Stearyl-R8 (STR-R8) yang dikenal sebagai
penginduksi fusi membran endosom. Kesimpulannya, vektor nano yang mengenkapsulasi siRNA target ke paru-
paru dapat dikembangkan dengan mengontrol panjang rantai PEG dan struktur vektor nano untuk target
intraselular secara efisien.
Kata kunci : Pulmonary, PEG moiety, Intracellular trafficking, Gen Endogen, Endosomal membrane inducer
squamous cell carcinoma, adenocarcinoma and large
cell carcinoma and represents approximately 80 % of
all lung cancers. Unfortunately, the majority of
INTRODUCTION
Lung cancer remains a major health problem as
the leading cause of cancer-related death worldwide [1].
Non Small Cell Lung Cancer (NSCLC) includes
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patients present with advanced NSCLC at the time of
iagnosis and die from the disease. First line therapy with
cisplatin-based chemotherapy showed modest benefit
with an extension in survival of approximately 2 months
[1,2]. The need for more effective treatments has led to
the development of new therapeutic approaches
targeting tumor biology.
Investigators in non viral vector development
have introduced a variety of strategies to overcome
barriers for macromolecules such as small interfering
Ribonucleic Acid (siRNA) delivery. These includes
cellular internalization, intracellular trafficking in
terms of endosomal escape and decoating process to
release siRNA to the cytoplasm. In addition, for
systemic in vivo applications, an important factors
should be considered, including physicochemical
properties that affect stability in the blood (i.e. particle
size and zeta potential of the vector) and the immune
system (i.e. reticuloendothelial system capture of
the vector) [3].
PEGylated nanoparticles with multiple
components are the most promising non viral vector for
systemic delivery. It was reported that nanoparticles
containing Polyethylene glycol (PEG), Solid NucleicAcid
Lipid Particles (SNALPs), targeted to specific tissue and
showed Ribonucleic acid interference (RNAi) mediated
gene silencing in hepatitis B [4]. Thus, it is expected that
the use of PEG moiety would promote to pulmonary
targeting. Additionally, the multiple components used
in the vector design would induce an efficient cytosolic
delivery of siRNA particularly an escape from the
endocytic vesicles and decoating process.
Angiogenesis, i.e. the formation of new blood
vessels, plays a central role in tumor growth, invasion,
metastasis, and thus represents an attractive therapeutic
target [1]. To date, a number of molecules regulating
angiogenesis have been described. Of these, Vascular
Endothelial Growth Factor (VEGF) is the most important
growth factor controlling angiogenesis in normal and
tumor cells [1,5]. The Vascular Endothelial Growth Factor
Receptor (VEGFR) family consists of six growth factors
includingVEGF-A,VEGF-B,VEGF-C, VEGF-D,VEGF-E
and placental growth factor (PIGF) which mediate their
angiogenic effects via three receptors, VEGFR1-3.
Binding of VEGF ligand to the receptor triggers
downstream signaling pathways involved in enhancing
vascular permeability, endothelial proliferation, invasion,
migration and survival. VEGFR-1 and VEGFR-2 are
important mediators of angiogenesis and VEGFR-3 is
involved in lymphangiogenesis [1].
In the present study, nanoparticles designed for
sophisticated lung targeting which addressed to knock
down endothelial VEGFR1 gene expressed in the
pulmonary endothelial cells were developed. In addition,
to induce prominent gene silencing of the nanoparticles,
the use of octaarginine (R8) as a fusogenic peptide
enhancer was demonstrated.
EXPERIMENTAL METHOD
Preparation of IRQ Modified Liposomes
Three types of [3H]CHE labeled liposomes,
conventional liposomes (Conv-Lip), IRQ-modified
liposomes (IRQ-Lip) 5% and IRQ-Lip 10% were prepared
by the hydration method. Those liposomes were labeled
with 0.03% of [3H]CHE. Conv-Lip were composed of
cholesteryl (Cho), Phosphatidylcoline (EPC) in a molar
ratio of 3 : 7. To prepare the IRQ-Lip, two concentrations
of Stearyl (STR)-IRQ were included (5 and 10 % of the
total lipid in the [3H]-Cho/EPC liposomes). These lipids
were dissolved in 125 L of chloroform and the solvent
was then removed by nitrogen gas under reduced
pressure in a glass tube to give a thin film. The lipid film
was hydrated with Phosphate Buffer Saline (PBS) (pH
7.4), vortexed for 5 sec and sonicated within 1 minute by
probe-type sonicator.
Synthesis of IRQ-PEG900-DOPE and IRQ-
PEG2000-DSPE
Synthesis of IRQ-PEG900-DOPE was performed
following the procedure used for the synthesis of
Cl31-PEG450-DOPE [6]. While IRQ-PEG2000-DSPE was
synthesized as described previously [6]. To attach the
IRQ to the surface of liposomes, the IRQ peptide was
modified by adding cysteine residues, so that peptide
can be readily conjugated to Mal-PEG-lipid to form the
IRQ-PEG-lipid. In this study, two types of PEG were used,
these were Mal-PEG900-NHS and Mal-PEG2000-DSPE. The
IRQ-PEG900-DOPE was synthesized by a two steps
reaction of NHS groups of Mal-PEG900-NHS and NH3
primer of DOPE resulted in Mal-PEG900-DOPE, followed
by reaction between moiety of Mal-PEG900-DOPE and
cystein of IRQ peptide. The former reaction was carried
out at room temperature for 2 hours in DMSO and the
molar ratio of Mal-PEG900-NHS, DOPE and triethylamine
were 0.4, 0.4 and 0.8 mol, respectively.
The latter synthesis was performed by coupling
of the thiol group of IRQ peptide and the maleimide of
Mal-PEG900-DOPE. IRQ peptide and Mal-PEG-lipid were
dissolved in H2O at concentrations of 10 mM and mixed
with equal ratios of 1 : 1. The reaction was carried out at
room temperature overnight. The product was then
identified by a Matrix-Assisted Laser Desorption/
Ionization Time-Of-Flight (MALDI-TOF) mass
spectrometry.
The IRQ-PEG2000-DSPE (distearoylphosphatidyl
ethanolamine) was synthesized by a single step reaction
of maleimide moiety of Mal-PEG2000-DSPE with
thiol groups of the IRQ as described in the latter
synthesis step of IRQ-PEG900-DOPE above. The
coupling between thiol group of peptide and the
maleimide of Mal-PEG2000-DSPE was performed as
described in the previous study [7].
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The product of IRQ-PEG2000-DSPE was
structurally confirmed by a MALDI-TOF mass
spectrometry. Sinapic acid was used as a matrix for
mass spectrometric analysis of the peptide product.
Sample solution was 5 L product in 100 L aqueous
solution of 30% acetonitrile containing 0.1%
Trifluoroacetic acid (TFA). Two L of aliquots were
spotted onto a MALDI-TOF target plate and analyzed
by a Voyager-DE PRO Mass Spectrometer (Applied
Biosystems, Foster City, CA).
Preparation of PEGylated Liposomes
(PEG-Lip) [3H]CHE labeled PEG-Lip was prepared
by hydration method. The liposomes were labeled with
[3H]CHE of around 0.03 %. Liposomes were basically
composed of EPC and Cho in a molar ratio of 7 : 3.
To prepare PEG-Lip, 10 % of Mal-PEG2000-DSPE was
incorporated into the liposomes.
Briefly, total lipids (1 mM) were dissolved in
ethanol solution in a glass tube. The maleimide-PEG-
lipid was added to the ethanol solution, followed by
addition of 125 L chloroform. The organic solvent
was evaporated by nitrogen gas. To obtain a
transparent and homogenous thin lipid film, 125 L
chloroform was added and evaporated. Aqueous phase
of PBS was added into a dried lipid film. The vesicles
were vortexed and sonicated in one minute by probe-
type sonicator. Liposome were stored at 4 oC for a
maximum of one week.
Preparation of IRQ-Modified PEGylated
Liposomes (IRQ-PEG-Lip)
Liposomes were basically composed of EPC
and Cho (7 : 3 molar ratio) and reaction mixture between
Mal-PEG2000-DSPE and IRQ (1 : 1) was incorporated
at 5 % of the total lipid. Liposomes were prepared
by hydration method. Briefly, total lipid (1 mM)
was dissolved in ethanol solution. The reaction mixture
was added to the ethanol solution. To increase
evaporation, 125 L of chloroform was added. The
organic solvent was evaporated by nitrogen gas in a
glass tube. To the obtained film, aqueous PBS 0.6 mL
was added and the glass tube was sonicated for 15 sec
in a bath type sonicator. The liposomes were then
purified by gel filtration on Sephadex G-100 column.
Liposomes were stored at 4 oC for a maximum of
one week.
Biodistribution of the Liposomes
In the preliminary study, five types of liposomes,
Conv-Lip, IRQ-Lip 5%, IRQ-Lip 10%, PEG2000-Lip,
IRQ-PEG2000-Lip 5%, were individually injected into a
8 weeks Balb/c mice via the tail vein. The liposomes
were fixed at 10 nmol lipid/g BW.After 6 hours, the mice
were sacrificed and their lung and liver were collected.
To obtain an actual uptake of liposomes in tissues, the
portion of liposomes in the vascular space was removed
by heart perfusion. After weighing, the samples were
solubilized in Soluene-350 for 5 hours at 50 oC. To
confirm lung accumulation, two types of liposomes,
IRQ-PEG900-Lip and IRQ-PEG2000-Lip, were independently
injected to each mouse.
Handling of the samples were the same
as described above. Radioactivities were then
determined by liquid scintillation counter, with
Hionic Fluor.
Preparation of IRQ-Modified Liposomes
Encapsulating siRNA
For transgene expression study, siRNA
was encapsulated in IRQ-Lip, IRQ-PEG900-Lip,
IRQ-PEG2000-Lip. These nanoparticles were prepared
using a hydration method. In this study, two types of
siRNA were used, each for luciferase gene and
endogenous VEGFR1 gene, respectively. siRNA
for luciferase gene was used in the preliminary
study to screen the potential formula and it
was encapsulated in all types of liposomes used.
An anti-luciferase siRNA was 21 mer and it
sequences were 5‘-GCGCUGCUGGUGCCAACCCTT-3‘,
5‘-GGGUUGGCACCAGCAGCAGCGCTT-3‘. Inthe latter
study, siRNA for VEGFR1 was encapsulated in the
IRQ-PEG900-Lip.
Firstly, siRNA and STR-R8, as a polycation
agents, were firstly dissolved in RNase-free
water. To condense the siRNA, the siRNA solution
was added to the polycation solution while vortexing
at room temperature.
The concentrations of both solutions were fixed
at 0.1 mg/mL. The siRNA/STR-R8 complexes were
prepared at a nitrogen/phosphate (N/P) ratio of 2.9. A
volume of 0.25 mL aliquot of condensed siRNA
suspension was added to the lipid film, which was formed
by evaporation of a chloroform solution of 137.5 nm lipids,
on the bottom of a glass tube followed by a 10-min
incubation at room temperature to hydrate the lipids. In
this experiment, the lipid composition used was
DOPE/PA/IRQ-PEG-lipid/Cho-GALAin a molar ratios of
7 : 2 : 1 : 0.1.
In the case of IRQ-PEG900-Lip encapsulating
siRNA for VEGFR1, STR-R8 of 5, 10 and 15 % of
the total lipids was incorporated to make a final
concentration of 0.55 mM. To coat condensed siRNA
with lipids, the glass tube was sonicated approximately
1 min in a bath-type sonicator (125 W, Branson
Ultrasonics, Danbury, CT). Liposomes were stored
at 4 oC for a maximum of one week. The size distribution
and zeta potential of each sample was determined
using a Zetasizer Nano ZS ZEN3600 (MALVERN
Instrument, Worchestershire, UK).
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Transgene Expression of IRQ-Modified
Liposomes Encapsulating siRNA
For transgene expression study of IRQ-PEG-Lips
coated anti-luciferase siRNA, 5 x 104 HeLa cells
stably expressing luciferase (108 RLU/mg protein)
were seeded onto a 24-well plate in 0.6 mL of Dulbecco`s
Modified Eagle`s Medium (DMEM) containing
10 % Fetal Calf Serum (FCS) and were incubated for
24 hours.
Before transfection, cells were washed with
0.5 mLPBS. IRQ-PEG-Lipscorresponding to 0.4gsiRNA
were suspended in 0.25 mL OPTI-MEM containing serum
and then were incubated with cells for 3 hours at 37 oC.
Next, 1 mL medium supplemented with serum was added
to the cells, followed by incubation for an additional
21 hours. After 24 hours, cells were washed with 0.5 mL
PBS and then were solubilized with reporter lysis buffer
(Promega, Madison, WI).
Luciferase activity was initiated by addition of
50 L of luciferase assay reagent (Promega, Madison,
WI) to 20 L of cell lysate and measured by means
of a luminometer (Luminescencer-PSN, ATTO, Japan).
The amount of protein in the cell lysate was measured
usig a BCA protein assay kit (PIERCE, Rockford, IL).
Results were expressed in relative light units
(RLU)/mg protein.
For transgene expression study of IRQ-PEG-Lips
coated anti-VEGFR1 siRNA, two days before infection,
2 x 105 Mouse fetal lung mesenchyme-4 (MFLM-4) cells
were seeded onto a 6-well plate in 2 mL of DMEM
containing 10 % FCS. Before transfection, cells were
washed with 1 mL DMEM. IRQ-PEG-Lips coated siRNA
corresponding to 6.4 g siRNA were suspended in 1 mL
DMEM containing 10 % FCS and were incubated with
cells for 3 hours at 37 oC. Two mL medium supplemented
serum was added to the cells, followed by incubation
for an additional 21 hours.
Cells were solubilized with 1 mL reporter
lysis buffer. mRNA was extracted from the samples
and converted to complementary DNA (cDNA) by
reverse transcriptase. The amount of cDNA was
determined by Real Time Polymerase Chain Reaction
(PCR). Results were expressed in percentage of
RNAi effect.
RESULTS AND DISCUSSION
The present studies aimed to develop an
intelligent delivery system which is able to selectively
target the lung and subsequently its endothelial cells.
In addition, the function of the developed nanoparticles
was examined by evaluating the delivery of
macromolecules siRNA to the cytosol of lung
endothelial cells.
Characterization of Prepared siRNA-Coated
IRQ-PEG-Lips
During preparation of the liposomes or coated
particles for the use of pharmacokinetics and transgene
expression studies in HeLa cells, the STR and the
maleimide moeity acted as an anchor to the lipid bilayer
leaving IRQ peptide freely attached to surface (IRQ-Lip)
or freely attached to the terminal of PEGylated liposomal
surface (IRQ-PEG-Lip). The size and  potential of
prepared nanoparticles are summarized in Table 1.
Particles for pharmacokinetics study had a size of around
80 nm. Incorporation of STR-IRQ to the Conv-Lip shifted
its charges from neutral to positive one. In addition, the
higher insertion density of the IRQ, the more positive
their charges since the IRQ peptide is rich in arginine
residues. When PEG moiety was inserted to the lipid
bilayer, the size was slightly increased.
Types of liposomes Size (nm) Zeta-potential (mV)
Conv-Lip 81  3.5 2  2.6
IRQ-Lip 5% 85  2.7 37  3.6
IRQ-Lip 10% 83  4.1 49  4.4
IRQ-PEG900-Lip 111  2.8 30  3.2
IRQ-PEG2000-Lip 107  3.1 7  1.8
Luciferase siRNA-IRQ-PEG900-Lip 117  4.6 24  4.1
Luciferase siRNA-IRQ-PEG2000-Lip 110  3.8 6  2.9
Table 1. The size and zeta-potential of prepared liposomes for
pharmacokinetics and transgene expression studies in HeLa cells
Figure 1. The tissue uptake of Conv-Lip, IRQ-Lip 5 %,
IRQ-Lip 10 %, mPEG-Lip and IRQ-PEG2000-Lip 5 %
in the lung and liver. The distribution was expressed as
the percentage injection dose per tissue (%ID/tissue) in
the lung (a) and liver (b). Open bars, light gray bars, gray
bars, dark gray bars and closed bars indicate the tissue
uptake at 6 hours after an i.v. injection of Conv-Lip,
IRQ-Lip 5 % and IRQ-Lip 10 %
(b)
(a)
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Furthermore, the use of long PEG moiety reduced
its charges. These results are in line with the fact that
the attachment of PEG moiety on the surface of
liposomes neutralizes the effect of any charged
component [7]. In general, IRQ-PEG900-Lip and
IRQ-PEG2000-Lip had comparable sizes. Similar tendencies
were observed for other coated particles between PEG900
and PEG2000 moeity, indicating that there were no
significant differences in the physicochemical properties
between PEG900- and PEG2000-modified nanoparticles.
Pharmacokinetics of IRQ-Lips and
IRQ-PEG2000-Lips
To determine in vivo distribution of IRQ-Lip,
the accumulation of IRQ-Lip with the density of 5 %
and 10 % in the lung were evaluated 6 hours after
i.v administration (Figure 1A) and then compared to
Conv-Lip as a control. The result showed that a small
amount of Conv-Lip was recovered in the lung with the
level of less than 1 % Injected Dose/g tissue (ID/g tissue).
Incorporation of STR-R8 at 5 and 10 % to liposomal
surface did not improve the uptake to the lung (Figure
1(a)). In addition, hepatic distribution was drastically
increased as the result of modification with R8
(Figure 1(b)). IRQ-Lips were accumulated in the liver
reaching approximately 80 %.
These results are in line with the previous study
showing that the liver was the major clearance uptake of
positively cationic liposomes [8]. It is possible that
IRQ-Lip could be recognized by various opsonins or
macrophages in the liver. When PEG2000 moiety was
incorporated into the liposomes and the terminal of PEG
moeity was conjugated with the IRQ, lung accumulation
was drastically enhanced to approximately 39 % ID/g
tissue at 6 hours post i.v. administration (Figure 1(a)).
It is likely that the use of PEG2000 moiety reduced the
recognition by opsonin so that liver accumulation was
lower compare to that of IRQ-Lips. These results revealed
that lung targeting of IRQ-modified nanoparticles could
be improved by the incorporation of PEG moiety.
Silencing Activity of IRQ-Lips and
IRQ-PEG2000-Lip
For examining the efficiency of the delivery of
macromolecules such as siRNA, we then compared the
two liposomes, IRQ-Lip and IRQ-PEG2000-Lip. When
siRNA for reporter luciferase gene was encapsulated in
IRQ-Lip, the transgene expression was knocked down
by approximately 50% (Figure 2). This result is consistent
with the previous study showing that gene silencing of
IRQ-Lip was occurred. IRQ-Lip was internalized into cells
via clathrin-mediated endocytosis and caveolar
endocytosis. Additionally, the IRQ peptide was
demonstrated to facilitate the escape from the endocytic
vesicles [9].
Although, it was internalized via two cellular
uptake pathways, it has been demonstrated that
Clathrin-Mediated Endocytosis (CME) is a responsible
pathway to induce RNA interference (RNAi) effect [10].
Therefore, after IRQ-Lip internalized through CME and
entrapped in the endosomes, the IRQ peptide mediates
endosomal escape. Thus, siRNA is released into the
cytosol after decoating process occurred. However,
when PEG moiety was inserted into the liposomes,
Figure 2. The effects of PEG moiety on the in vitro gene
silencing of luciferase gene expression using siRNA.
HeLa cells stably expressing luciferase were independently
transfected with IRQ-Lip or IRQ-PEG2000-Lip
containing luciferase or GFP. Luciferase activities were
measured 24 hours after transfection and were expressed
as percentage of silencing effect. The data represent as
the mean of three data.
Figure 3. The tissue uptake of IRQ-PEG2000-Lip 5 %,
unmodified PEG900-Lip and IRQ-PEG900-Lip in the
lung and liver. The distribution was expressed as the
percentage injection dose per tissue (%ID/tissue) in the
lung (a) and liver (a). Light gray bars, gray bars and closed
bars indicate the tissue uptake at 6 hours after
an i.v. injection of IRQ-PEG2000-Lip 5 %, unmodified
PEG900-Lip and IRQ-PEG900-Lip, respectively. The
data represent mean SE (n = 3).
(a)
(b)
Jurnal Sains Materi Indonesia
Indonesian Journal of Materials Science
Vol. 12, No. 2,Februari 2011, hal : 145 - 152
ISSN : 1411-1098
150
transgene expression was severely inhibited (Figure 2).
It was reported that the PEG moiety does not inhibit
the endosomal escape, but it impaired the decoating
process [6]. Decoating process is occurred subsequently
during fusion step between liposomal membranes and
endosomal membrane. It is presumable that length of
PEG interrupts the interaction between the two
membranes so that siRNA is still encapsulated in the
lipid vesicles. Based on the results of pharmacokinetics
and in vitro gene silencing studies, the use of PEG
has advantages and disadvantageous that is termed as
PEGdilemma.
Pharmacokinetics of IRQ-PEG900-Lip and
IRQ-PEG2000-Lip
An alternative strategy to solve these hurdles is
by modifying length of PEG moiety. The hypothesized
that shorter PEG length would not only facilitate lung
targeting of IRQ-Lip, but also compromise with the
fusion process of the membranes to induce cytosolic
release of siRNA. To confirm lung targeting by
utilizing shorter PEG moiety, we first individually injected
[3H]-IRQ-PEG900-Lip and [
3H]-IRQ-PEG2000-Lip and
specific the lung accumulation was observed at 6 hours
and 24 hours post i.v. administration. The use of short
PEG900 moeity exhibited comparable results compared to
that of PEG2000 moeity. At the same indicated time, the
IRQ-PEG900-Lip was taken up by the lung of approximately
37 % ID/g tissue. Moreover, the lung accumulation of
the IRQ-PEG900-Lip and IRQ-PEG2000-Lip were 34 % and
31 % ID/g tissue at 24 hours post i.v. administration
(Figure 3(a)).
These results exhibited that the uptake of the
IRQ-PEG-Lips in the lung remained after 24 hours and
its accumulation was enhanced by 18.5 fold compared
to that of unmodified PEG900-Lip. This observation
depicted their actual uptake in the lung because an
impurity of the nanoparticles in the vascular space was
removed by heart perfusion technique. These results
indicated that lung accumulation of IRQ-modified
liposomes can be achieved by shortening the PEG
moiety approximately PEG900. As to the accumulation of
the nanoparticles in the liver, it is likely that modification
of PEG moiety did not affect in liver uptake. The
nanoparticles were taken up by the liver in a range of
approximately 50-60 % ID/g tissue (Figure 3(b)). High
liver accumulation can not be avoided since the positive
charges of IRQ-nanoparticles were also responsible for
the uptake.
Thus, it is hypothesized that flexibility of the
IRQ to interact with its receptor was enhanced by
modifying the PEG moiety. It is probable that an
interaction between the IRQ with its receptor on the
surface of lung endothelial cells is more prominent
when the IRQ was attached to the tip of PEG moiety
rather than attachment to liposomal surfaces.
Therefore, the IRQ peptide would more freely reach the
receptor compared to that of direct attachment to surface
of the liposomes.
Transgene Expression of IRQ-PEG-Lips
CoatedAnti Luciferase siRNA
To investigate the function of IRQ-PEG-Lips,
firstly siRNA for luciferase gene was encapsulated in
the nanoparticles. After 24 hours post transfection to
the HeLa stably expressing luciferase, the RNAi effect
was determined. When siRNA was encapsulated in
IRQ-PEG2000-Lip, transgene knocked down was
limited approximately to 11 % (Figure 4). This result
was consistent with the previous study whose
results showed that the use of PEG moiety
inhibited the decoating of lipid vesicles [6].
When PEG2000 moeity attached was replaced with
the shorter PEG900 moiety, RNAi effect was also
inhibited in the absence of fusogenic peptide
GALA. However, with incorporation of GALA to
the surface of liposomes, transgene expression was
drastically enhanced to approximately 53 % (Figure 4).
GALA is a pH sensitive fusogenic peptide
(WEAALAEALAEALAEHLAEALAEALE-ALAA) in
the form of Cholesteryl-GALA (Cho-GALA) to modify
the lipid vesicles. It was reported that it improved
Types of liposomes Size (nm) Zeta-potential (mV)
IRQ-PEG900-Lip 84  4.8 19  5.3
IRQ-PEG900-Lip + STR-R8 5% 116  3.9 43  2.6
IRQ-PEG900-Lip + STR-R8 10% 122  3.2 51  3.4
IRQ-PEG900-Lip + STR-R8 15% 117  4.3 44  4.9
Table 2. The size and zeta-potential of IRQ-PEG900-Lips
coated anti-VEGFR1 siRNA for transgene expression studies
in MFLM-4 cells.
Figure 4. The effects of different PEG length on the in
vitro gene silencing of luciferase gene expression
using siRNA. HeLa cells stably expressing luciferase
were independently transfected with IRQ-PEG-Lips
containing luciferase or GFP. The cells were treated
with IRQ-PEG2000-Lip, IRQ-PEG2000-Lip containing
GALA, IRQ-PEG900-Lip and IRQ-PEG900-Lip
containing GALA. Luciferase activities were measured
24 hours after transfection and were expressed as
percentage of silencing effect. The data are represented
as the mean of three data.
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transfection activity of encapsulating plasmid DNA
due to an enhanced endosomal release [11]. It is
presumably that during the IRQ mediates escape
nanoparticles from the endosomes, this synthetic
pH-responsive pore-forming peptide at the N-terminus
of the vectors assisted the escape of the cargo into
cytosol by effectively fused with the endosomal
membranes and disrupted their integrity [12].
Transgene Expression of IRQ-PEG-Lips
CoatedAntiVEGFR1 siRNA
Since the IRQ-PEG900-Lip exhibited high lung
accumulation and prominent gene silencing in vitro, it
is then addressed to deliver its content of siRNA to the
primary barrier of the lung endothelial cells. Thus, siRNA
for marker luciferase gene was replaced by siRNA for
specific endothelial gene marker. In this study, expression
of several endothelial gene markers in the lung
endothelial MFLM4 cells, such as CD31, Tie-2,
VEGFR-1 and VEGFR-2, were examined.
The results showed that VEGFR-1 and VEGFR-2
were expressed in high level in MFLM4 cells
(unpublished data). We then focused on the VEGFR-1
gene since it plays an important role in angiogenesis. To
examine silencing activity in the endothelial cells,
nanoparticles encapsulating synthetic double-stranded
anti-VEGFR-1 siRNA (21 base pairs) were tested for their
ability to deliver siRNA to the cytosol and to elicit an
RNA interference effect. Physical characteristics of
prepared nanoparticles was shown in Table 2. Inclusion
of STR-R8 to the liposomes resulted in increasing size
and charge of nanoparticles. However, similar tendencies
in size and charge of coated particles modified R8
indicating that there were no significant changes in their
physicochemical properties. As a result, siRNA-IRQ-
PEG900-Lips equivalent to 6.4 g of siRNA resulted in
15% silencing of VEGFR1 activity (Figure 5). However,
when stearyl-R8 was incorporated to the liposomal
surfaces, RNAi effects was improved. Particularly,
inclusion of
STR-R8 15 % to the total lipid vesicles resulted in
drastically enhancement in transgene knocked down to
approximately 46%. The enhancement of RNAi effect by
the use of STR-R8 15 % was 3-fold compared to that
without STR-R8. It was very clear the effects of STR-R8
on gene silencing of IRQ-PEG900-Lip in the MFLM4 cells.
Principally, the nanoparticles have designed to overcome
hurdles in intracellular targeting. They were equipped
with fusogenic lipid 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE), the IRQ peptide and the
Cho-GALA. The presence of the DOPE affects an
acidification in the endocytic vesicles so that fusion
occurs between the liposomal membrane and endosome
during escape [13].
Secondly, the use of IRQ promotes the endosomal
escape by fusion-independent mechanism. Lastly, the
Cho-GALA is expected to induce pore-formation of
endocytic vesicles at low pH compartment so that
decoating process is induced. Collectively, siRNAwould
be released in high extent to the cytoplasm. However,
novel strategy should be implemented to improve the
cytosolic release due to the low RNAi effect.
In the present study, we utilized the R8 which is
incorporated to the surface of liposomes by the use of
stearyl moiety as an anchor. Fusion to endosome was
postulated as the main mechanism of escape. For fusion
to take place between different membranes, three steps
are required specific recognition of the site of fusion,
close apposition of membranes and fusion or
coalescence of membranes [13,14].
At decreasing endosomal pH, the total positive
charge on IRQ-PEG-Lips containing R8 remains high
due to full protonation of all arginine moieties [13,15]. In
addition, R8 interact efficiently with amphoteric
components embedded in the endosomal membrane even
at acidic pH, not only through electrostatic interactions,
but more importantly through bidentate hydrogen
bonding. R8 seems to play an additional role in enhancing
fusion through insertion into the endosomal membrane
after being neutralized by negatively charged membrane
components.
The formed ion pair may insert into the membrane
and move inwards, driven by the transmembrane
potential. This is expected to bring the lipid film of the
liposome into intimate contact with the endosomal
membrane, resulting in their fusion. This action is
thought to increase at acidic pH when the potential
across the endosomal membrane is high [13,16].
Oligo and polyarginines were reported to bind to
anionic membrane-bound fatty acid salts, cholesterol
derivatives, or phosphatidyl glycerol to form
hydrophobic ion pairs that are soluble in chloroform or
octanol [13,15,17].
Figure 5. The effects of incorporation of STR-R8 on the
in vitro silencing of VEGFR1 gene expression using siRNA.
MFLM-4 cells were independently transfected by
IRQ-PEG900-Lips containing VEGFR1 or GFP. The
cells were treated with IRQ-PEG900-Lips without
incorporation of R8 (R8 0 %), incorporation of R8 5 %,
10 % and 15 %.VEGFR1 activities were measured
24 hours after transfection and were expressed as
percentage of silencing effect. The bars represent the
mean of three data.
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CONCLUSION
The use of long PEG2000 moiety drastically
improved lung accumulation. However, it provided poor
transgene expression. The use of short PEG900 moiety
exhibited a high pulmonary uptake, comparable to long
PEG2000 moiety. In addition, the use of IRQ-PEG900-Lip
containing siRNA for VEGFR1 in combination with the
R8 showed prominent gene silencing in pulmonary
endothelial cells. Collectively, the use of PEG900 moiety
and its incorporation along with the R8 into the
IRQ-modified nanoparticles is promising vector design
for efficient pulmonary targeting as well as the
subsequent pulmonary endothelial cells targeting.
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